Zoetis Falls 57% From Its High, Yet the Model Signals Buy

Zoetis Inc. shares trade at $79.00, about 57% below their two-year high and near the bottom of their range. Reports tie the sell-off to two cuts to the company’s 2026 guidance and weaker US demand for pet-health products. Yet the underlying business still earns a 40.7% operating margin and generates $2.0B of free cash flow, and this Zoetis Inc. stock analysis explains why our scoring model rates the stock a Buy despite flat revenue.

What Is Happening With the Stock Price

Zoetis’s two-year range runs from $69.69 to $181.95, so at $79.00 the shares sit in the lower end of the range, roughly 13% above the low. The market capitalization is $32.64B. According to reports, the shares fell sharply after first-quarter results missed expectations, and the company lowered its full-year outlook again in August, citing weaker demand in the US companion-animal market and increased competition. A decline of this size shows how much investor confidence has been shaken.

Quality: Is This a Financially Sound Business?

Quality scores 87/100. Profitability remains excellent: a 71.7% gross margin, a 40.7% operating margin and a 27.7% net profit margin. Free cash flow of $2.0B over the trailing twelve months, on $9.5B of revenue, shows earnings converting well into cash. Return on assets is 15.3%.

Leverage needs a closer look. Debt-to-equity is 2.94, which is high, and it also helps explain the 64.9% return on equity and the 10.39 price-to-book ratio: a smaller equity base inflates both figures. Liquidity is solid, with a current ratio of 3.08 and a quick ratio of 1.57. The dividend yields 2.6% on a payout ratio of 33.9%, leaving room for reinvestment. For this Zoetis Inc. stock analysis, the quality picture is of a highly profitable, cash-generative business carrying meaningful debt.

Growth: Does This Company Have Real Upside?

Growth scores 50/100, and this is where the concern lies. Revenue fell 0.2% over the trailing twelve months and earnings grew just 1.2%, well below the 5.4% five-year revenue CAGR. Flat sales point to the demand pressure reported in the US pet-care business. Whether growth resumes depends on how quickly that market stabilizes and how the company responds to competition. EV/Revenue of 4.27 is moderate for a business with margins this high.

Opportunity: Is Now a Good Time to Enter?

Opportunity scores 72/100. The P/E of 12.99 on earnings per share of $6.08 and EV/EBITDA of 10.00 are low for a business with a 40.7% operating margin, and the free cash flow yield of 6.2% adds support. The main exception is price-to-book of 10.39, which is inflated by the leveraged balance sheet. The stock’s position near the lower end of its two-year range could interest contrarian investors, but a low price can also reflect a lasting change in the growth outlook rather than a mispricing.

Zoetis Inc. Stock Analysis: The Bottom Line

StreetBriefs’ scoring model rates Zoetis a Buy, with a Recommendation Score of 70/100, driven by strong quality (87/100) and attractive valuation (72/100). The bull case is a highly profitable business, $2.0B of free cash flow, a 2.6% dividend and a P/E of 12.99 after a steep share-price decline. The bear case is flat revenue, repeated guidance cuts, competition in its core pet-health market and debt-to-equity of 2.94. The main risk is that weaker demand persists, in which case today’s low multiples may prove justified rather than a discount.

This Zoetis Inc. stock analysis presents the Buy as a quantitative model signal for further research, not a personalized recommendation to transact. Investors weighing the name might watch whether revenue growth returns in the coming quarters. All equities carry risk, and a falling share price can keep falling.